Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in AMD (QUATRO)
NCT02158624Unknown
- Sponsor
- Kyushu University
- Start
- Dec 2013
- Primary completion
- Apr 2015
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ranibizumab in age-related macular degeneration (AMD), sponsored by Kyushu University. Primary endpoints: Best Corrected Visual Acuity at 3 months and Quality of Life at 3 months. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT02158624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02158624.